

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lipton et al.
Application No.: 10/810,848
Filing Date: March 26, 2004
Title: TREATMENT OF DEMYELINATING CONDITIONS
Attorney Docket No.: 507 US

Examiner: Carlic K. Huynh
Art Unit: 1612
Confirmation No. 9106

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the restriction requirement mailed August 9, 2007, Applicants elect the invention of Group 1 (claims 1-10, and 15-17) without traverse, and further elect memantine as the species of an uncompetitive NMDA receptor channel antagonist. Claims 1-10 and 15-17 encompass the elected species.

The fee for a four-month extension of time is being submitted herewith in accordance with 37 CFR 1.136. If anything further is required, please contact the undersigned.

Respectfully submitted,

Dated: January 8, 2008

/Jan P. Brouard, Reg. No. 35,081/

Jan P. Brouard, Reg. No. 35,081
Adamas Pharmaceuticals, Inc.
Phone: (510) 450-3507
Customer No.: 72664